GlassScriptPhysician profile
Clara Markovits
NPI 1699879767
$6,650.65
in general payments reported to CMS, 2019-2025
20 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $643 · 2021: $966 · 2022: $1,027 · 2023: $1,125 · 2024: $836 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,610 · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,610.13 |
| Education | $383.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,107.51 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $1,150.68 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Novartis Pharmaceuticals Corporation | $667.11 | 2019-2025 | |
| Abbvie INC. | $536.65 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.69 | 2021-2025 | Ofev, Spevigo |
| Glaxosmithkline, LLC. | $433.46 | 2019-2024 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $331.36 | 2021-2025 | Saphnelo |
| Pfizer INC. | $244.36 | 2019-2021 | |
| Ucb, INC. | $156.39 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $101.17 | 2019-2025 | Orencia |
| Genentech USA, INC. | $88.87 | 2019 | |
| Depuy Synthes Sales INC. | $74.15 | 2019-2022 | |
| Horizon Therapeutics Plc | $72.92 | 2020-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $60.13 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $35.74 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.71 | 2024 | Strensiq |
| Vyera Pharmaceuticals, LLC | $17.84 | 2019 | |
| Genzyme Corporation | $16.95 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Markovits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.